Cognyte Software (NASDAQ:CGNT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Cognyte Software (NASDAQ:CGNTGet Free Report) issued its quarterly earnings data on Tuesday. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03, Briefing.com reports. Cognyte Software had a negative return on equity of 5.98% and a negative net margin of 3.70%. The firm had revenue of $82.70 million during the quarter, compared to the consensus estimate of $82.05 million. During the same period in the previous year, the firm posted ($0.25) EPS. The company’s quarterly revenue was up 12.7% compared to the same quarter last year. Cognyte Software updated its FY25 guidance to ($0.07) EPS and its FY 2025 guidance to -0.070–0.070 EPS.

Cognyte Software Price Performance

CGNT traded down $0.17 during trading on Thursday, hitting $7.43. The company’s stock had a trading volume of 646,896 shares, compared to its average volume of 368,700. The firm’s 50 day moving average price is $7.39 and its 200-day moving average price is $7.10. The stock has a market cap of $527.68 million, a PE ratio of -44.71 and a beta of 1.74. Cognyte Software has a twelve month low of $4.00 and a twelve month high of $8.70.

Institutional Trading of Cognyte Software

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC increased its holdings in shares of Cognyte Software by 30.3% during the 1st quarter. Acadian Asset Management LLC now owns 2,304,970 shares of the medical device company’s stock worth $19,041,000 after buying an additional 536,393 shares during the last quarter. G2 Investment Partners Management LLC increased its holdings in shares of Cognyte Software by 241.5% during the 4th quarter. G2 Investment Partners Management LLC now owns 1,366,163 shares of the medical device company’s stock worth $8,784,000 after buying an additional 966,163 shares during the last quarter. Essex Investment Management Co. LLC increased its holdings in shares of Cognyte Software by 1.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 339,452 shares of the medical device company’s stock worth $2,807,000 after buying an additional 5,244 shares during the last quarter. Scalar Gauge Management LLC acquired a new stake in shares of Cognyte Software during the 4th quarter worth $2,001,000. Finally, Phoenix Holdings Ltd. increased its holdings in shares of Cognyte Software by 33.0% during the 3rd quarter. Phoenix Holdings Ltd. now owns 279,400 shares of the medical device company’s stock worth $1,344,000 after buying an additional 69,400 shares during the last quarter. 72.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Evercore ISI lifted their price objective on Cognyte Software from $5.00 to $7.50 and gave the stock an “in-line” rating in a research report on Wednesday, April 10th. Needham & Company LLC restated a “hold” rating on shares of Cognyte Software in a research report on Tuesday. Wedbush boosted their price target on Cognyte Software from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Thursday. Finally, StockNews.com downgraded Cognyte Software from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 13th.

Get Our Latest Stock Report on Cognyte Software

Cognyte Software Company Profile

(Get Free Report)

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.

Featured Articles

Earnings History for Cognyte Software (NASDAQ:CGNT)

Receive News & Ratings for Cognyte Software Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognyte Software and related companies with MarketBeat.com's FREE daily email newsletter.